AbbVie sues over selection of Botox for IRA negotiations

Nicole DeFeudis / endpoints - AbbVie is suing CMS for picking Botox for the third round of Medicare negotiations, making it the first drugmaker to challenge the upcoming cycle in court. In a lawsuit filed Wednesday in Washington, DC, AbbVie ...

AI Summary: AbbVie has filed suit challenging the federal decision to include Botox in Medicare’s drug price negotiation program, arguing the selection process was flawed and that the move could imperil innovation and pricing strategies. The lawsuit seeks to block or alter implementation while the industry and regulators brace for legal precedent.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

HHS drops 340B pilot following court rulings / 3 months

HHS scraps 340B rebate pilot following court rulls / 3 months

FTC settles insulin lawsuit forces Express Scripts policy changes / 3 months

Judge blocks 340B drug pricing pilot program implementation / 4 months

CMS Unveils Medicaid Drug Pricing Model with Most-Favored Nation Approach / 6 months

Optum Rx/Caremark and FTC edge toward settlement in insulin case / 2 months

Life-extending prostate cancer drug to be offered to thousands in England / 4 months